GSA Capital Partners LLP Takes Position in Organogenesis $ORGO

GSA Capital Partners LLP acquired a new stake in Organogenesis (NASDAQ:ORGO) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 191,465 shares of the company’s stock, valued at approximately $992,000.

A number of other hedge funds have also made changes to their positions in the business. Creative Planning increased its holdings in shares of Organogenesis by 8.2% in the 3rd quarter. Creative Planning now owns 38,279 shares of the company’s stock valued at $162,000 after acquiring an additional 2,887 shares during the last quarter. BNP Paribas Financial Markets increased its holdings in shares of Organogenesis by 57.0% in the 3rd quarter. BNP Paribas Financial Markets now owns 14,522 shares of the company’s stock valued at $61,000 after acquiring an additional 5,273 shares during the last quarter. Quarry LP purchased a new position in shares of Organogenesis in the 3rd quarter valued at about $25,000. State of Alaska Department of Revenue purchased a new position in shares of Organogenesis in the 3rd quarter valued at about $25,000. Finally, Flagship Harbor Advisors LLC purchased a new position in shares of Organogenesis in the 4th quarter valued at about $34,000. Hedge funds and other institutional investors own 49.57% of the company’s stock.

Insider Buying and Selling at Organogenesis

In related news, Director Michael Joseph Driscoll bought 10,000 shares of the stock in a transaction on Monday, March 9th. The shares were bought at an average cost of $2.67 per share, for a total transaction of $26,700.00. Following the purchase, the director owned 225,707 shares of the company’s stock, valued at $602,637.69. This trade represents a 4.64% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 33.00% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on ORGO. Wall Street Zen downgraded Organogenesis from a “buy” rating to a “sell” rating in a report on Saturday, May 9th. Weiss Ratings downgraded Organogenesis from a “hold (c)” rating to a “sell (d)” rating in a research note on Monday, May 11th. Finally, BTIG Research downgraded Organogenesis from a “buy” rating to a “neutral” rating in a research note on Friday, May 8th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $8.50.

Organogenesis Trading Up 4.3%

NASDAQ:ORGO opened at $2.66 on Friday. The stock’s 50 day moving average price is $2.44 and its 200 day moving average price is $3.77. The company has a market capitalization of $342.29 million, a PE ratio of -14.00 and a beta of 1.31. The company has a quick ratio of 3.16, a current ratio of 3.53 and a debt-to-equity ratio of 0.05. Organogenesis has a 52-week low of $2.04 and a 52-week high of $7.08.

Organogenesis (NASDAQ:ORGO) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.08). The firm had revenue of $37.23 million for the quarter, compared to analysts’ expectations of $43.26 million. Organogenesis had a positive return on equity of 9.63% and a negative net margin of 0.84%.

Organogenesis Company Profile

Organogenesis Inc operates as a regenerative medicine company focused on the development, manufacturing and commercialization of therapeutic solutions for wound care, surgical repair and sports medicine. The company’s product portfolio addresses a range of acute and chronic tissue repair needs, leveraging bioengineered skin substitutes, human placental-derived products and other allografts designed to promote healing and reduce scarring. Organogenesis markets its therapies to hospitals, outpatient clinics, wound care centers and other healthcare providers.

Key offerings include Apligraf, a living skin substitute for treatment of diabetic foot ulcers and venous leg ulcers; Dermagraft, a cryopreserved human fibroblast-derived dermal substitute; Grafix, a placental membrane allograft for complex and chronic wounds; and TheraSkin, a cryopreserved human skin allograft used in surgical and reconstructive procedures.